The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00285597
Verified October 2009 by National Heart and Lung Institute. Recruitment status was: Active, not recruiting
This is a double-blind, placebo-controlled, cross-over study evaluating the effects of UDCA on peripheral blood flow and immune function in patients with stable chronic heart failure (CHF). Sixteen patients with CHF will be recruited from the heart failure clinic at the Royal Brompton Hospital. Following baseline evaluation, patients will be randomised to receive either placebo or UDCA at a dose of 1000 mg/day for a period of four weeks. They will then undergo repeat evaluation (peripheral blood flow and immune function). A four week washout period will then take place before the patients cross-over to receive the respective other therapy for a further four weeks (i.e. those first receiving placebo will go onto receive UDCA and vice versa). The study will be completed after a total of twelve weeks, with a final assessment (peripheral blood flow and immune function).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
age >21 years
of either sex
the patient is willing and capable of complying with the requirements of this protocol
the patient has provided written informed consent
the patient has clinical evidence of chronic heart failure:
reduced ejection fraction (≤40%) or left ventricular impairment on echocardiography (LVEDD ≥60mm)
stable clinical condition and medication for at least 1 month prior to the study (New York Heart Association class II-IV).
the patient is receiving appropriate conventional medical therapy for heart failure (ACE inhibitor or angiotensin II blocker, diuretics, beta-blocker as indicated and tolerated).
congenital heart disease
any life-threatening disease, other than heart failure
active malignancy of any type, or history of a malignancy within previous 5 years. Patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrolment are acceptable.
previous heart transplant
severe neuro-muscular disease
history of unstable angina, myocardial infarction or stroke within 3 months prior to the study
pregnancy or women of child-bearing age
treatment with immunosuppressive therapy e.g. steroids for rheumatoid arthritis or obstructive lung disease
significant renal dysfunction (serum creatinine >250mmol/l), severe liver disease (liver function tests > 3 times normal)
unable to understand and comply with protocol or to give informed consent